it is important to note you were wrong with the peri trial and a lot of people respected your opinion that it would be successful. i was one of them. i think there will be good news released in the near future. if the fda accepts aezs-130 nda you don't think there will be a spike. 130 for cancer cachexia could be positive an update could be soon. why wouldn't an update on aezs-108 for breast or prostate not mean much. how do you know any partnership for anything in their pipeline is unlikely. my predictions are just as likely to happen as yours. if your that skeptical why do you hold any aezs stock at all. this post like yours has no substance just speculation. as with all bios they can either soar or disappoint.
the 2 new positions will not add to the cash burn since the german research team was reduced from 120 to 70 with the selling of cetrotide manufacturing. the aezs-130 nda wasn't 3 years in preparation as you said. aezs had to add more patients to the original study and the results were released 6/26/2012 a little over a year ago. they got the U.S.patent 8/7/12 and the euro one 9/25/12. a delay in filing a nda is not uncommon in bios. 23 million in cash at the end of year with no debt is a lot more than most bios with no revenue have. they also have 10 million extra towards the aezs-108 trial. aezs-108 is a delivery system so we should have some results with the phase 2 trials before the phase 3 is completed. aezs' pipeline is a lot better than most . if aezs-108 works it can be used for numerous cancers. when nda is submitted we will see a pop this quarter. there have been large bids from 60k to 90k the past week that took long to fill. retail was selling and larger buyers were establishing positions in this under-valued company.
with low market cap and float this stock will rise. watching it for a while. this is a good entry point with news coming out soon. r/s is all day traders now they will move on and investors will move in.